- Conditions
- Parkinson's Disease Dementia
- Interventions
- Rivastigmine capsule, Rivastigmine transdermal patch
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 583 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Reseda, California + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bioavailability
- Interventions
- Rivastigmine (RLD) transdermal patch, Rivastigmine (generic) transdermal patch
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Parkinson Disease, Parkinson Disease Dementia
- Interventions
- Rivastigmine transdermal patch
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Parkinson's Disease, Mild Cognitive Impairment
- Interventions
- Exelon Patch (rivastigmine transdermal system), Placebo Patches
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Alzheimer Disease, Healthy Aging
- Interventions
- BrightGo cognitive training, Standard of Care medication for early Alzheimer's Disease
- Device · Drug
- Lead sponsor
- Bright Cloud International Corp
- Industry
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- New Brunswick, New Jersey • North Brunswick, New Jersey
- Conditions
- Alzheimer's Disease
- Interventions
- Rivastigmine 4.6 mg/24 h (5 cm^2), Rivastigmine 9.5 mg/24 h (10 cm^2), Rivastigmine 13.3 mg/24 h (15 cm^2), Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 716 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 93
- States / cities
- Tempe, Arizona • Tucson, Arizona • Conway, Arkansas + 84 more
- Conditions
- Alzheimer Disease
- Interventions
- Rivastigmine 5 cm^2, Rivastigmine 10 cm^2, Rivastigmine 15 cm^2, Placebo to 15 cm^2 patch, Placebo to 10 cm^2 patch
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 1,584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 61 more
- Conditions
- Alzheimer's Disease
- Interventions
- Rivastigmine 5 cm^2 transdermal patch, Rivastigmine 10 cm^2 transdermal patch
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 23
- States / cities
- Sun City, Arizona • Costa Mesa, California • Fresno, California + 20 more
- Conditions
- Alzheimer's Disease, Dementia, Alzheimer Type
- Interventions
- rivastigmine transdermal patch
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 1,040 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 22
- States / cities
- Orange, California • San Francisco, California • Boca Raton, Florida + 19 more
- Conditions
- Traumatic Brain Injury, Cognitive Impairment
- Interventions
- Rivastigmine Transdermal Patch
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 8
- States / cities
- San Diego, California • Miami, Florida • Tampa, Florida + 5 more
- Conditions
- Mild Cognitive Disorder, Mild Cognitive Impairment
- Interventions
- Exelon [rivastigmine] transdermal patch, Placebo transdermal patch
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Hallucinations, Auditory, Psychosis
- Interventions
- Rivastigmine Transdermal System, Scopolamine, Placebo Patch
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2032
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut